Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 47 results found. Search for [ gilead coronavirus medicine ]

Results 20 to 40 of 47
E Kumar Sharma
New Delhi, June 21, 2020
Cipla plans to launch the drug in a couple of days, while Hetero's drug is expected to hit the market in a week


BusinessToday.In
New Delhi, June 15, 2020
Coronavirus vaccine update: The Health Ministry has included the use of antiviral drug Remdesivir as part of its investigational therapy for restricted emergency use


BusinessToday.In
New Delhi, June 14, 2020
Remdesivir can be administered to patients with moderate disease (those on oxygen), though it should not administered to patients with severe renal impairment, pregnancy or lactating females and children, health ministry guidelines suggest


BusinessToday.In
June 9, 2020
The Centre has sought stakeholders' comments on the rules in the draft rules within 15 days, following which it will be reviewed for final notification


BusinessToday.In
June 7, 2020
Gilead was contacted last month by AstraZeneca about the possibilities of merger. In case the deal happens, it would bring together two firms leading the drug industry's efforts to fight the coronavirus pandemic


BusinessToday.In
New Delhi, June 6, 2020
The drug will be provided to the poor and needy patients in the state, Public Health Minister Rajesh Tope said


BusinessToday.In
June 4, 2020
A Gilead spokesperson told the daily that the manufacturers have been given the authority to set their own prices for the drug


PTI
June 2, 2020
The drug has been allowed for restricted emergency use for treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children hospitalised with severe symptoms, subject to several safeguards, the source said


PTI
May 30, 2020
Gilead Sciences Inc have entered into non-exclusive licensing agreements with pharma firms including three domestic majors Cipla, Jubilant Life Sciences and Hetero for manufacture and distribution of remdesivir


BusinessToday.In
May 24, 2020
Coronavirus vaccine update: Experts have welcomed the findings, saying the results showed patients on remdesivir cut their recovery time by 27 per cent


PTI
May 18, 2020
Bangladesh has so far reported 20,995 coronavirus cases. A total of 314 people have lost their lives in the country due to the disease


Reuters
May 15, 2020
Gilead on Tuesday said it had signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of remdesivir in more than 120 mostly low-income countries in Southeast Asia, Africa and other parts of the world


BusinessToday.In
May 13, 2020
Jubilant Life Sciences share price opened with a gain of 5% at Rs 429.95 against the previous closing price of Rs 409.50


BusinessToday.In
May 13, 2020
Sensex, Nifty Live News Today: ICICI Bank, L&T, M&M, Maruti and Hero MotoCorp were among the top performers on NSE today. On the contrary, Nestle, Sun Pharma, HCL Tech, Airtel and Adni Ports were the top losers. Expert view over market reaction on stimulus announcement


BusinessToday.In
May 13, 2020
Stocks to watch today on May 13: Jubilant Life Sciences, Vedanta, NMDC, Nestle, Bandhan Bank, Maruti Suzuki, Siemens among others are the top stocks to watch out for in Wednesday's trading session.


BusinessToday.In
May 12, 2020
The non-exclusive licensing agreement between Jubilant Life Services and Gilead Sciences allows the former to to register, manufacture and sell remdesivir in 127 countries, including India


BusinessToday.In
New Delhi, May 11, 2020
Coronavirus news: Speaking about a treatment for coronavirus, researcher Ahmad Sedaghar said that experimental drugs such as Gilead's remdesivir can only be effective if the person is diagnosed early


Reuters
May 9, 2020
The findings, published in the Lancet medical journal, showed that on average, people who got the triple drug reached the point of no detectable virus five days earlier than those in the control group - at 7 days versus 12 days


Reuters
May 8, 2020
Among patients given hydroxychloroquine, 32.3% ended up needing a ventilator or dying, compared with 14.9% of patients who were not given the drug


Reuters
May 8, 2020
With no other approved treatments for COVID-19, interest in the drug is growing around the world. Administered by intravenous infusion, it was granted authorisation last week by the U.S


PAGES 2 OF 3  123